Axovia’s lead program AXV101 is an adeno-associated virus (AAV9)-based investigational gene therapy that aims to slow down or ...

The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...

The French biotech company Nanobiotix announced today that it has dosed the first patient in the CONVERGE study, a Phase 2 ...

Josh Gissing is Cluster Head (UK, Ireland & Nordics) for Biocon Biologics: a biosimilars company whose business model seeks ...

The Swedish biotech hopes its precision therapy will help patients with advanced solid tumors who currently have few ...

As Director of R&D at Sunflower Therapeutics, Laura Crowell works with a team developing biologic medicines and vaccines. She ...

Diane Lacroix, Vice President of Clinical Data Management at eClinical Solutions, talks personalised medicine, data decisions ...